Get the Stockscreener App
15.52
5.51%
0.81
After Hours:
15.37
-0.15
-0.97%
Vor Biopharma Inc stock is traded at $15.52, with a volume of 675.87K.
It is up +5.51% in the last 24 hours and down -14.02% over the past month.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
See More
Previous Close:
$14.71
Open:
$14.82
24h Volume:
675.87K
Relative Volume:
0.69
Market Cap:
$758.11M
Revenue:
-
Net Income/Loss:
$-695.98M
P/E Ratio:
-0.0472
EPS:
-328.6331
Net Cash Flow:
$-143.65M
1W Performance:
+7.93%
1M Performance:
-14.02%
6M Performance:
-25.78%
1Y Performance:
+28.41%
1-Day Range:
$14.71
$15.60
1-Week Range:
$13.66
$15.60
52-Week Range:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
15.52 | 718.55M | 0 | -695.98M | -143.65M | -328.63 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Jefferies | Buy |
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Dec-17-25 | Initiated | TD Cowen | Buy |
| Dec-09-25 | Initiated | JP Morgan | Overweight |
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Six new Vor Bio hires get stock awards priced at $13.85 - Stock Titan
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in April - MarketBeat
Vor Biopharma (NASDAQ: VOR) files resale registration for 5.34M shares - Stock Titan
Vor Biopharma (NASDAQ: VOR) plans virtual 2026 meeting and equity plan changes - Stock Titan
[ARS] Vor Biopharma Inc. SEC Filing - Stock Titan
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Wall Street analysts predict a 107.82% upside in Vor Biopharma (VOR): Here's what you should know - MSN
Vor Bio announces $75M private placement - MSN
Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 Shares - MarketBeat
Ra capital healthcare fund sells 165,150 Vor Biopharma shares for $2.6m By Investing.com - Investing.com Australia
Ra capital healthcare fund sells 165,150 Vor Biopharma shares for $2.6m - Investing.com UK
RA Capital fund trims Vor Biopharma (NASDAQ: VOR) stake with 165,150-share sale - Stock Titan
VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage - MSN
Vor Biopharma (VOR) Cost Structure | Q4 2025: EPS Exceeds ExpectationsGDR - Xã Vĩnh Công
Vor Biopharma(VOR.US) 10% Shareholder Sells US$10.17 Million in Common Stock - Moomoo
Ra Capital sells $10.17 million of Vor Biopharma common stock By Investing.com - Investing.com Australia
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc - GuruFocus
Vor Biopharma (NASDAQ:VOR) Director Sells $7,462,931.08 in Stock - MarketBeat
Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 171,963 Shares of Stock - MarketBeat
Ra Capital sells $10.17 million of Vor Biopharma common stock - Investing.com
RA Capital trims Vor Biopharma (VOR) stake, still owns 19.9% - Stock Titan
RA Capital fund trims Vor Biopharma (VOR) stake with 630K-share sale - Stock Titan
Vor Biopharma (NASDAQ:VOR) Shares Down 4.4%Here's What Happened - MarketBeat
Vor Biopharma (VOR) Stock Volume Stability (Drops Sharply) 2026-04-20High Attention Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect? - Yahoo Finance
Vor Biopharma (VOR) Stock: Is It Respecting Levels (Investor Interest) 2026-04-18Index Investing - Cổng thông tin điện tử Tỉnh Sơn La
Vor Biopharma (NASDAQ:VOR) Trading 9.7% HigherWhat's Next? - MarketBeat
Jeremy Brett Sokolove Net Worth (2026) - GuruFocus
Vor Biopharma Q1 EPS Estimate Increased by HC Wainwright - MarketBeat
H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
VOR Forecast, Price Target & Analyst Ratings | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
VOR Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $31 - GuruFocus
Ra Capital Management, L.P. Sells 530,610 Shares of Vor Biopharma (NASDAQ:VOR) Stock - MarketBeat
RA Capital sells Vor Biopharma (VOR) shares worth $11.8 million By Investing.com - Investing.com India
RA Capital sells Vor Biopharma (VOR) shares worth $11.8 million - Investing.com
Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 153,735 Shares of Stock - MarketBeat
Vor Biopharma (NASDAQ:VOR) Director Sells $858,840.44 in Stock - MarketBeat
RA Capital reports 19.9% Vor Biopharma (VOR) stake after share sales - Stock Titan
RA Capital entities trim Vor Biopharma (VOR) stake with 738K-share open-market sale - Stock Titan
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):